• What is Welichem’s business?
  
  
• What are the key elements of Welichem’s technology?
  
  
• What is Welichem’s market focus?
  
  
• What stage is Welichem at?
  
  
• What are Welichem’s competitive advantages?
  
  
• What is Welichem’s commercialization strategy?

What is Welichem’s business?

• Developing and commercializing new therapeutics for autoimmune/ inflammatory diseases and cancer.
• Producing better therapeutics based on a novel source of compounds from symbiotic microorganisms.
• Unique compounds discovered by Welichem principals, leading scientists in symbiotic microorganisms, through more than 25 years of research.

What are the key elements of Welichem’s technology?

• Compounds have exceptionally effective bioactivities - immunomodulation & anti-proliferative.
• Existing evidence shows high efficacy with low or no toxicity.
• Compounds originate from natural process that has existed for millions of years – less likelihood of unknowns to occur through clinical trials.
• Pipeline of other ultra high quality drug leads – technology has already yielded many bioactive, small molecules in over 10 different classes of chemicals that exhibit a range of anti-inflammatory, antimicrobial and anti-proliferative (i.e. anti-cancer and anti-psoriatic) bioactivities.

What is Welichem’s market focus?

• Large target Markets with unmet needs.
• Psoriasis $4.4 billion.
• Eczema $4.0 billion.
• Potential for Inflammatory bowel diseases (IBD) - $1.6 billion.

What stage is Welichem at?

• First drug candidate is halfway through preclinical development.
• Our second drug candidate will be focused on cancer, another kind of cell proliferative disease.

What are Welichem’s competitive advantages?

• Compared with existing drugs, Welichem’s therapeutics offer the potential of safer treatments with greater efficacy and faster relief.

What is Welichem’s commercialization strategy?

• Complete development to clinical phase II.
• License to Pharma for upfront & milestone payments, then ongoing royalties.
• Budget of $12 million to complete Phase II clinical trials.